Thank you for donating!
You can donate using the following services.
Donate Today
Search
Need support today?
Email: info@npuk.org
Helpline: 0191 415 0693
Main menu
Niemann-Pick Disease
About Us
Care & Support
Research
Fundraising
Resources
Blog
News
NPUK Shop
COVID-19
News
NPUK
>
News
14.02.22
IB1001-301: Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study
Read more
11.02.22
Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States
Read more
03.02.22
Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C
Read more
01.02.22
Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO
Read more
07.12.21
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
Read more
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
Next
Clinical Trials
CTD Holdings Inc
IntraBio
News
NPUK Annual Family Conference
NPUK News
Orphazyme
Sanofi Genzyme
The Quinn Madeline Foundation
Uncategorized
Donate today
Follow NPUK
Contact us
Donate today
Email: info@npuk.org
Helpline: 0191 415 0693